CTOs on the Move

Abeona Therapeutics

www.abeonatherapeutics.com

 
Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company`s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company`s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Brian Kevany
Chief Technical Officer Profile

Funding

Abeona Therapeutics raised $15.5M on 08/03/2015
Abeona Therapeutics raised $13.8M on 10/16/2017
Abeona Therapeutics raised $92M on 10/19/2017
Abeona Therapeutics raised $103.5M on 12/28/2019

Similar Companies

Scios

Scios Inc. is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UBC Heart + Lung Institute

UBC Heart + Lung Institute is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vericel

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.

Center for Breakthrough Medicines

The Center for Breakthrough Medicines is the Worlds Largest and Most Advanced Single Solution Cell and Gene Therapy Contract Development and Manufacturing Organization. Period.

TransMolecular

TransMolecular, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.